查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1580102

道斯症候群市場：依治療類型、通路分類 - 全球預測 2025-2030 年

Doose Syndrome Market by Treatment Type (Non-Pharmacological Treatments, Pharmacological Treatments), Distribution Channels (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年道斯症候群市場價值為9.9882億美元，預計到2024年將達到11.3775億美元，複合年成長率為14.27%，到2030年將達到25.4211億美元。

道斯症候群，也稱為肌陣攣靜態癲癇 (MAE)，主要影響兒童，表現為肌陣攣和靜態癲癇發作的組合。這種罕見疾病的市場開拓包括開發創新的基因測試、客製化抗癲癇藥物以及旨在改善患者預後的客製化治療。未滿足的醫療需求和對特異性治療的需求不斷成長，需要關注未滿足的關鍵字。應用在兒科神經病學、遺傳諮詢和個人化醫療領域尤其重要，最終用途擴展到醫院、專科診所和研究機構。該市場受到有影響力的成長要素的支持，例如神經遺傳學的進步、醫療保健支出的增加和意識的提高。特別是，開發非侵入性診斷工具和先進治療通訊協定（包括基於大麻二酚的治療和基因治療）存在機會。生物技術公司和醫療保健提供者之間的策略夥伴關係可以增加治療選擇並促進新的突破。儘管有這些機遇，但挑戰仍然存在，包括高昂的研發成本、治療的潛在副作用以及由於疾病的罕見性而導致大規模臨床試驗的不足。新治療方法核准流程的複雜性加劇了這些限制。在創新方面，人工智慧和巨量資料的交叉為預測診斷和治療效率評估提供了一個有前景的研究領域。在市場研究中，患者登記和縱向研究可以提供有關疾病進展和治療反應的重要見解。總體而言，KEYWORD市場的特點是其利基性質，這需要製藥公司、研究人員和政策制定者共同努力，克服障礙並抓住機會。透過策略性地瞄準這些市場動態，相關人員可以加強開發平臺，並最終改善遭受此挑戰的人們的生活品質。

主要市場統計
基準年[2023] 99882萬美元
預測年份 [2024] 11.3775億美元
預測年份 [2030] 25.4211億美元
複合年成長率（%） 14.27%

市場動態：揭示快速發展的道斯症候群市場的關鍵市場洞察

道斯綜合症市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 政府和非營利組織支持罕見疾病研究和患者照護的努力
    • 採用個人化醫療方法來改善道斯綜合症治療中的患者治療效果
    • 製藥公司與研究機構合作開發道斯綜合症標標靶治療
    • 透過增加針對罕見癲癇症的臨床試驗的資金來加速新藥的發現
  • 市場限制因素
    • 道斯綜合症新療法的嚴格監管要求和漫長的核准流程阻礙了快速進入市場
    • 關於道斯症候群的全面認知和教育計劃尚未普及到基層醫療醫生和公眾，這阻礙了早期診斷和治療。
  • 市場進入機會
    • 為受道斯症候群影響的家庭建立專門的病患支援服務和資源
    • 開發綜合數位平台來追蹤和監測道斯症候群症狀和治療
    • 與醫療保健提供者合作，將道斯症候群治療通訊協定納入標準護理中。
  • 市場挑戰
    • 道斯綜合症治療的高昂治療費用和有限的保險範圍使許多家庭無法接受。
    • 研究和進行道斯症候群等罕見疾病臨床試驗的挑戰正在減緩新治療方法的開發。

波特五力：駕馭道斯症候群市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解道斯症候群市場的外部影響

外部宏觀環境因素在塑造道斯綜合症市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解打瞌睡症候群市場的競爭狀況

對道斯綜合症市場的詳細市場佔有率分析可以對供應商的業績進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣劑量症候群市場供應商績效評估

FPNV 定位矩陣是評估道斯症候群市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了打瞌睡症候群市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對道斯綜合症市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 政府和非營利組織支持罕見疾病研究和患者照護的努力
      • 採用個人化醫療方法可改善道斯綜合症治療中的患者治療效果
      • 製藥公司與研究機構合作開發道斯症候群的標標靶治療
      • 增加對罕見癲癇臨床試驗的資助，以加速新藥發現
    • 抑制因素
      • 嚴格的監管要求和新治療方法漫長的核准流程阻礙了道斯症候群的快速市場進入
      • 基層醫療醫生和公眾缺乏對道斯症候群的全面認知和教育計劃，阻礙了早期診斷和治療
    • 機會
      • 為受道斯症候群影響的家庭建立專門的病患支援服務和資源
      • 開發一個全面的數位平台來追蹤和監測症狀和治療
      • 與醫療保健提供者合作，將道斯症候群治療通訊協定納入護理標準
    • 任務
      • 道斯症候群治療的高昂治療費用和有限的保險範圍使許多家庭無法接受。
      • 研究和進行道斯綜合症等罕見疾病臨床試驗的挑戰正在減緩新治療方法的開發
  • 市場區隔分析
    • 治療類型：非藥物療法在兒科患者治療的應用
    • 分銷管道：利用零售藥房治療慢性和急性期劑量綜合症
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章道斯症候群市場（依治療類型）

  • 非藥物治療
    • 生酮飲食
    • 迷走神經刺激
  • 藥物治療
    • 抗癲癇藥
    • 大麻二酚產品
    • 皮質類固醇
    • 免疫球蛋白

第 7 章道斯症候群市場（依通路）

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第8章美洲道斯症候群市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太道斯症候群市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲/中東/非洲道斯症候群市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Jazz Pharmaceuticals 已啟動 Epidiolex 治療 Dawes 症候群的 3 期試驗，以減少癲癇發作並擴大其市場佔有率。
  • 戰略分析和建議

公司名單

  • BioMarin Pharmaceutical
  • Cerecor
  • Eisai Co.
  • Greenwich Biosciences
  • GW Pharmaceuticals
  • INSYS Therapeutics
  • Johnson & Johnson
  • Lundbeck
  • Marinus Pharmaceuticals
  • Neurelis
  • Ovid Therapeutics
  • Pfizer
  • PTC Therapeutics
  • Purdue Pharma
  • Sanofi
  • Sunovion Pharmaceuticals
  • Supernus Pharmaceuticals
  • Takeda Pharmaceutical Company Limited
  • Upsher-Smith Laboratories
  • Zogenix
Product Code: MRR-3204321AF692

The Doose Syndrome Market was valued at USD 998.82 million in 2023, expected to reach USD 1,137.75 million in 2024, and is projected to grow at a CAGR of 14.27%, to USD 2,542.11 million by 2030.

Doose Syndrome, also referred to as Myoclonic-Astatic Epilepsy (MAE), primarily affects children and presents with a combination of myoclonic and astatic seizures. The market scope for this rare disorder includes the development of innovative genetic testing, bespoke antiepileptic drugs, and tailored therapeutics aimed at improving patient outcomes. The necessity of focusing on Doose Syndrome stems from unmet medical needs and the increasing demand for specifically-targeted treatments. Applications are particularly pertinent in pediatric neurology, genetic counseling, and personalized medicine sectors, with the end-use scope covering hospitals, specialized clinics, and research institutions. The market is buoyed by influencing growth factors such as advances in neurogenetics, increased healthcare expenditure, and heightened awareness. Opportunities are notably present in the development of non-invasive diagnostic tools and advanced treatment protocols, including cannabidiol-based therapies and gene therapy. Strategic partnerships between biotech firms and healthcare providers can enhance therapeutic options and foster novel breakthroughs. Despite these opportunities, challenges persist, including the high costs of research and development, potential side effects of treatments, and the inadequacy of large-scale clinical trials due to the syndrome's rarity. These constraints are exacerbated by the complexity of regulatory approval processes for new therapies. Regarding innovation, the intersection of artificial intelligence and big data presents promising research areas for predictive diagnostics and treatment efficiency assessment. In conducting market research, leveraging patient registries and longitudinal studies can offer vital insights into disease progression and therapeutic response. Overall, the Doose Syndrome market is characterized by its niche nature, necessitating collaboration among pharmaceutical companies, researchers, and policymakers to overcome barriers and capitalize on opportunities. By strategically targeting these market dynamics, stakeholders can enhance the development pipeline and ultimately improve quality of life for individuals affected by this challenging condition.

KEY MARKET STATISTICS
Base Year [2023] USD 998.82 million
Estimated Year [2024] USD 1,137.75 million
Forecast Year [2030] USD 2,542.11 million
CAGR (%) 14.27%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Doose Syndrome Market

The Doose Syndrome Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Government and non-profit organization initiatives to support research and patient care for rare diseases
    • Adoption of personalized medicine approaches improving patient outcomes in the management of Doose syndrome
    • Collaboration between pharmaceutical companies and research institutions to develop targeted therapies for Doose syndrome
    • Increased funding for clinical trials focusing on rare epileptic conditions promoting new drug discoveries
  • Market Restraints
    • Strict regulatory requirements and lengthy approval processes for new therapies for Doose syndrome hindering faster market entry
    • Lack of comprehensive awareness and education programs about Doose syndrome among primary care physicians and the general public impairing early diagnosis and treatment
  • Market Opportunities
    • Establishing specialized patient support services and resources for families affected by Doose syndrome
    • Developing a comprehensive digital platform for tracking and monitoring Doose syndrome symptoms and treatment
    • Partnering with healthcare providers to integrate Doose syndrome treatment protocols into standard care practices
  • Market Challenges
    • High cost of treatment and limited insurance coverage for Doose Syndrome management reducing accessibility for many families
    • Challenges in conducting research and clinical trials for rare diseases like Doose Syndrome leading to slower development of new therapies

Porter's Five Forces: A Strategic Tool for Navigating the Doose Syndrome Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Doose Syndrome Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Doose Syndrome Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Doose Syndrome Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Doose Syndrome Market

A detailed market share analysis in the Doose Syndrome Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Doose Syndrome Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Doose Syndrome Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Doose Syndrome Market

A strategic analysis of the Doose Syndrome Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Doose Syndrome Market, highlighting leading vendors and their innovative profiles. These include BioMarin Pharmaceutical, Cerecor, Eisai Co., Greenwich Biosciences, GW Pharmaceuticals, INSYS Therapeutics, Johnson & Johnson, Lundbeck, Marinus Pharmaceuticals, Neurelis, Ovid Therapeutics, Pfizer, PTC Therapeutics, Purdue Pharma, Sanofi, Sunovion Pharmaceuticals, Supernus Pharmaceuticals, Takeda Pharmaceutical Company Limited, Upsher-Smith Laboratories, and Zogenix.

Market Segmentation & Coverage

This research report categorizes the Doose Syndrome Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment Type, market is studied across Non-Pharmacological Treatments and Pharmacological Treatments. The Non-Pharmacological Treatments is further studied across Ketogenic Diet and Vagus Nerve Stimulation. The Pharmacological Treatments is further studied across Antiepileptic Drugs, Cannabidiol Products, Corticosteroids, and Immunoglobulins.
  • Based on Distribution Channels, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Government and non-profit organization initiatives to support research and patient care for rare diseases
      • 5.1.1.2. Adoption of personalized medicine approaches improving patient outcomes in the management of Doose syndrome
      • 5.1.1.3. Collaboration between pharmaceutical companies and research institutions to develop targeted therapies for Doose syndrome
      • 5.1.1.4. Increased funding for clinical trials focusing on rare epileptic conditions promoting new drug discoveries
    • 5.1.2. Restraints
      • 5.1.2.1. Strict regulatory requirements and lengthy approval processes for new therapies for Doose syndrome hindering faster market entry
      • 5.1.2.2. Lack of comprehensive awareness and education programs about Doose syndrome among primary care physicians and the general public impairing early diagnosis and treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Establishing specialized patient support services and resources for families affected by Doose syndrome
      • 5.1.3.2. Developing a comprehensive digital platform for tracking and monitoring Doose syndrome symptoms and treatment
      • 5.1.3.3. Partnering with healthcare providers to integrate Doose syndrome treatment protocols into standard care practices
    • 5.1.4. Challenges
      • 5.1.4.1. High cost of treatment and limited insurance coverage for Doose Syndrome management reducing accessibility for many families
      • 5.1.4.2. Challenges in conducting research and clinical trials for rare diseases like Doose Syndrome leading to slower development of new therapies
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment Type: Application of non-pharmacological treatment in doose syndrome treatment for pediatric patient
    • 5.2.2. Distribution channel: Utilization of retail pharmacies for chronic and acute phase of doose syndrome
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Doose Syndrome Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. Non-Pharmacological Treatments
    • 6.2.1. Ketogenic Diet
    • 6.2.2. Vagus Nerve Stimulation
  • 6.3. Pharmacological Treatments
    • 6.3.1. Antiepileptic Drugs
    • 6.3.2. Cannabidiol Products
    • 6.3.3. Corticosteroids
    • 6.3.4. Immunoglobulins

7. Doose Syndrome Market, by Distribution Channels

  • 7.1. Introduction
  • 7.2. Hospital Pharmacies
  • 7.3. Online Pharmacies
  • 7.4. Retail Pharmacies

8. Americas Doose Syndrome Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Doose Syndrome Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Doose Syndrome Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
    • 11.3.1. Jazz Pharmaceuticals launches phase 3 trial of epidiolex for doose syndrome, aiming to reduce seizures and expand market presence
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. BioMarin Pharmaceutical
  • 2. Cerecor
  • 3. Eisai Co.
  • 4. Greenwich Biosciences
  • 5. GW Pharmaceuticals
  • 6. INSYS Therapeutics
  • 7. Johnson & Johnson
  • 8. Lundbeck
  • 9. Marinus Pharmaceuticals
  • 10. Neurelis
  • 11. Ovid Therapeutics
  • 12. Pfizer
  • 13. PTC Therapeutics
  • 14. Purdue Pharma
  • 15. Sanofi
  • 16. Sunovion Pharmaceuticals
  • 17. Supernus Pharmaceuticals
  • 18. Takeda Pharmaceutical Company Limited
  • 19. Upsher-Smith Laboratories
  • 20. Zogenix

LIST OF FIGURES

  • FIGURE 1. DOOSE SYNDROME MARKET RESEARCH PROCESS
  • FIGURE 2. DOOSE SYNDROME MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DOOSE SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DOOSE SYNDROME MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DOOSE SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS DOOSE SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS DOOSE SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES DOOSE SYNDROME MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES DOOSE SYNDROME MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC DOOSE SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC DOOSE SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA DOOSE SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA DOOSE SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. DOOSE SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. DOOSE SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DOOSE SYNDROME MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DOOSE SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DOOSE SYNDROME MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DOOSE SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DOOSE SYNDROME MARKET DYNAMICS
  • TABLE 7. GLOBAL DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DOOSE SYNDROME MARKET SIZE, BY KETOGENIC DIET, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DOOSE SYNDROME MARKET SIZE, BY VAGUS NERVE STIMULATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DOOSE SYNDROME MARKET SIZE, BY ANTIEPILEPTIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DOOSE SYNDROME MARKET SIZE, BY CANNABIDIOL PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DOOSE SYNDROME MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DOOSE SYNDROME MARKET SIZE, BY IMMUNOGLOBULINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL DOOSE SYNDROME MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL DOOSE SYNDROME MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL DOOSE SYNDROME MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS DOOSE SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES DOOSE SYNDROME MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC DOOSE SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA DOOSE SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 190. DOOSE SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 191. DOOSE SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023